Scipher Medicine: Reginald Seeto, Glenn Muir

Scipher Medicine, which markets the PrismRA blood test to guide precision rheumatoid arthritis therapy, has appointed Reginald Seeto as CEO and president. Seeto was previously CEO and president of CareDx. Prior to that, he was chief operating officer at Ardelyx, and before that, executive VP of corporate development and strategy at MedImmune, the biologics division of AstraZeneca. Earlier in his career, he held leadership positions at Boehringer Ingelheim and Organon. He began his career as a physician-scientist with both clinical and research roles and worked as a strategy consultant at McKinsey & Company.

Scipher also said that it recently appointed Glenn Muir as independent director of its board and chair of the audit committee. Muir has more than 30 years of life sciences industry experience. Most notably, he spent 26 years at Hologic, where he served as CFO and executive VP. He currently serves on the boards of directors for several publicly traded life sciences companies, including Repligen, G1 Therapeutics, and Neuronetics. He has also held board positions at ReWalk Robotics and RainDance Technologies.